A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.

Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

— Lupa-01  

Official title:

An Observational Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04751162
• Other study ID #: ML42283
• Status: Completed
• Start date: February 18, 2021
• Est. completion date: May 1, 2023

Study information

• Verified date: June 2023
• Source: Hoffmann-La Roche
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The current research is a non-interventional (NIS) study seeking to support objective Performance Status (PS) assessments in the particular context of metastatic NSCLC adult patients. To do so, the study comprises two phases. Phase I addresses a feasibility mixed-methods (quantitative-qualitative) approach. It primarily focuses on examining perceived technology usability in a limited sample of participants and feasibility of translating the actigraph data into PS scores (focus expert group). Phase II focuses on to primarily examine associations between technology collected data and ECOG-PS in a larger sample of participants.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 71
• Est. completion date: May 1, 2023
• Est. primary completion date: May 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria

Participants must meet the following criteria for study entry:

• 18 or more years of age.

• Able to understand and provide the study informed consent.

• Able to demonstrate basic digital literacy (e.g. knows how to communicate through instant messaging apps or similar).

• ECOG PS of 0, 1 or 2 assessed by physician.

• Life expectancy = 12 weeks

• Histopathologically or cytologically confirmed Non-small cell lung cancer (NSCLC) according to the International Association for the Study of Lung Cancer (IASLC) histopathological classification. Mixed or combined subtypes with component of small cell lung cancer according to the IASLC are not allowed.

• Metastatic NSCLC participants.

• Able to receive 1st line specific antitumor therapy defined by local practice and decision of attended oncologist.

Exclusion Criteria

Participants who meet any of the following criteria will be excluded from study entry:

• Any medical or social condition deemed by the investigator to be likely to interfere with a participant's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

• Participants with advanced LC and a known sensitizing driver mutation: activating EGFR mutation, ALK gene rearrangement, ROS1+ gen rearrangement, BRAF mutation.

• Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.

Uncontrolled tumor-related pain. Participants requiring pain medication must be on a stable regimen at study entry. Symptomatic lesions amenable to palliative radiotherapy (e.g., bone metastases or metastasis causing nerve impingement) should be treated prior to enrollment. Asymptomatic metastatic lesions whose further growth would likely cause functional deficits or intractable pain (e.g., epidural metastasis that is not presently associated with spinal cord compression) should be considered for locoregional therapy if appropriate prior to enrollment.

• Pregnant or breastfeeding woman.

• Leptomeningeal disease.

• Participants with any of the following central nervous system (CNS) metastases:

• Symptomatic CNS metastases with need of increasing doses of corticosteroids.

• Carcinomatous meningitis.

• Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for = 2 weeks prior to study entry.

• Oncological history:

• Have a previous or concurrent cancer that is distinct in primary (non-pulmonary) site or histology, except carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors (Ta and Tis [carcinoma in situ]) or any previous cancer curatively treated with last specific treatment more than 3 years ago without evidence of recurrence.

• Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or ductal carcinoma in situ treated surgically with curative intent).

Severe cardiovascular and pulmonary disease (e.g. myocardial infarction, unstable angina pectoris, coronary angioplasty or stenting, deep vein thrombosis, stroke, pulmonary fibrosis, active uncontrolled bleeding, or a known bleeding diathesis) less than 6 months before inclusion. New York Heart Association Class III or IV congestive heart failure, ventricular arrhythmias, or uncontrolled blood pressure.

• Any psychiatric diagnosis.

• Observed cognitive impairment or disease with cognitive impairment such as Alzheimer's Disease or Parkinson's Disease

• Severe infections within 4 weeks prior to randomization including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia

• Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis.

• Inability to understand the local language.

• Allergic to dedicated wearable material.

• Currently enrolled in a Clinical Trial.

Related Conditions & MeSH terms

• Lung Neoplasms
• Non-Small Cell Lung Cancer (NSCLC)

Intervention

Device:
• Actigraphy device (wearable) and mobile application
Participants will be asked to wear an actigraphy device (wearable) and to install a mobile application on their smartphones (cf. Broderick et al., 2019) for tracking PA, SQ and symptoms for 3 weeks

Locations

Country	Name	City	State
Spain	Fundacion Hospital de Alcorcon	Alcorcon	Madrid
Spain	Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia	Barcelona
Spain	Hospital Universitari de Girona Dr Josep Trueta; Departamento de Oncologia Medica	Girona
Spain	Hospital Universitario Clínico San Cecilio; Servicio de oncologia	Granada
Spain	Hospital 12 de Octubre; Servicio de Digestivo	Madrid
Spain	Hospital La Paz	Madrid
Spain	Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia	Murcia
Spain	Hospital Universitario Virgen del Rocio; Servicio de Oncologia	Sevilla
Spain	Hospital Sant Pau i Santa Tecla; Servicio de Oncologia	Tarragona
Spain	Hospital Universitario la Fe; Servicio de Oncologia	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Hoffmann-La Roche

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	ECOG-PS assessment of LC participants measured by clinical investigators	ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)	From baseline up to 9 months
Primary	ECOG-PS assessment of LC participants measured by data collected through wearable and a mobile application	ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)	From baseline up to 9 months
Primary	Usability of the mobile application perceived by clinical investigators	System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.	From baseline up to 9 months
Primary	Usability of the mobile application perceived by LC participants	System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.	From baseline up to 9 months
Primary	Usability of the wearable device perceived by LC participants	System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.	From baseline up to 9 months
Primary	Usability of the wearable device perceived by clinical investigators	System Usability: SUS questionnaire (Brooke, 1986) and usability questionnaire adapted from (Kim et al., 2017). This is a 10-item scale based on a 5-point Likert response measuring strength and agreement of usability. Total scores range from 0 to 100 with score = 68 considered acceptable usability.	From baseline up to 9 months
Secondary	Sensitivity to changes in ECOG-PS over time measured by clinical investigators	ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)	From baseline up to 9 months
Secondary	Sensitivity to changes in ECOG-PS over time measured by wearable and mobile application	ECOG-PS: Eastern Cooperative Oncology Group Performance Status (Oken et al., 1982)	From baseline up to 9 months